| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 860.31% | RBC Capital | $7 → $6 | Maintains | Outperform |
| 10/05/2023 | 1020.36% | RBC Capital | → $7 | Reiterates | Outperform → Outperform |
| 08/15/2023 | 1020.36% | RBC Capital | → $7 | Reiterates | Outperform → Outperform |
| 08/15/2023 | 700.26% | SVB Securities | $10 → $5 | Maintains | Outperform |
| 08/15/2023 | 1500.51% | HC Wainwright & Co. | $10 → $10 | Reiterates | Buy → Buy |
| 07/31/2023 | 1500.51% | EF Hutton | → $10 | Initiates Coverage On | → Buy |
| 07/05/2023 | 1500.51% | HC Wainwright & Co. | $33 → $10 | Reiterates | Buy → Buy |
| 05/10/2023 | 5181.69% | HC Wainwright & Co. | $35 → $33 | Maintains | Buy |
| 05/09/2023 | 1020.36% | RBC Capital | $8 → $7 | Maintains | Outperform |
| 05/08/2023 | 1660.56% | SVB Securities | $11 → $11 | Maintains | Outperform |
| 03/27/2023 | 2460.82% | Oppenheimer | $14 → $16 | Maintains | Outperform |
| 03/14/2023 | 1180.41% | RBC Capital | → $8 | Reiterates | → Outperform |
| 03/14/2023 | 5501.79% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 11/11/2022 | 1180.41% | RBC Capital | $10 → $8 | Maintains | Outperform |
| 11/10/2022 | 1660.56% | SVB Securities | → $11 | Maintains | Outperform |
| 05/03/2021 | 5501.79% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
| 04/26/2021 | 2780.92% | SVB Leerink | → $18 | Initiates Coverage On | → Outperform |
| 03/25/2021 | 7102.3% | Evercore ISI Group | → $45 | Initiates Coverage On | → Outperform |
What is the target price for Viracta Therapeutics (VIRX)?
The latest price target for Viracta Therapeutics (NASDAQ: VIRX) was reported by RBC Capital on November 10, 2023. The analyst firm set a price target for $6.00 expecting VIRX to rise to within 12 months (a possible 860.31% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Viracta Therapeutics (VIRX)?
The latest analyst rating for Viracta Therapeutics (NASDAQ: VIRX) was provided by RBC Capital, and Viracta Therapeutics maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Viracta Therapeutics (VIRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viracta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viracta Therapeutics was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
Is the Analyst Rating Viracta Therapeutics (VIRX) correct?
While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a maintained with a price target of $7.00 to $6.00. The current price Viracta Therapeutics (VIRX) is trading at is $0.62, which is out of the analyst's predicted range.
